Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tosedostat in MDS After HMA Failure
NCT02452346Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Mar 2015
- Primary completion
- Oct 2017
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tosedostat in myelodysplastic syndrome (MDS), sponsored by Weill Cornell Medicine. Started Mar 2015; status: completed.
02
Drugs
tosedostat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02452346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452346.